Avastin (bevacizumab) 400 mg, ROCHE, Germany

Indications:

• Treatment of metastatic colorectal cancer:
• in combination with chemotherapy based on fluoropyrimidine derivatives.
• Treatment of metastatic breast cancer
• first line treatment in combination with paclitaxel;
• first-line treatment in combination with capecitabine (when treatment with other chemotherapy regimens, including taxanes or anthracyclines, is considered inappropriate). Patients who have received adjuvant taxane and anthracycline-based regimens within the past 12 months should not be treated with Avastin in combination with capecitabine.
• Treatment of advanced unresectable, metastatic, or recurrent non-small cell lung cancer, excluding predominantly squamous cell lung cancer:
• first line treatment in combination with chemotherapy based on platinum derivatives.
• Treatment of advanced and/or metastatic renal cell carcinoma:
• first line therapy in combination with interferon alfa-2a.
• Treatment of advanced (FIGO stages III B, III C, and IV) epithelial ovarian, fallopian tube, and primary peritoneal cancers in adults:
• as first line therapy in combination with carboplatin and paclitaxel.
• Treatment of the first recurrence of epithelial ovarian cancer, fallopian tube and primary peritoneal cancer sensitive to treatment with platinum drugs:
• in combination with carboplatin and gemcitabine in adult patients who have not received previous therapy with bevacizumab or other vascular endothelial growth factor inhibitors or agents whose action is directed at the vascular endothelial growth factor receptor.
• Treatment of recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer resistant to platinum treatment:
• in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin in adult patients who have received no more than two previous chemotherapy regimens and have not previously received bevacizumab or other VEGF inhibitors or drugs whose action is directed to the VEGF receptor.
• Treatment of persistent, recurrent, or metastatic cervical cancer
• in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in adult patients who cannot receive platinum therapy.
• ovastin, altuzan, oltuzan, avostin, ovostin